Aurinia Pharmaceuticals 2024年第四季度GAAP每股收益$0.01超出$(0.02)的预期,销售额$59.87M低于$59.94M的预期

财报速递
27 Feb
Aurinia Pharmaceuticals (NASDAQ:AUPH) 报告称季度每股收益为$0.01,超过了分析师一致预期的$(0.02),超出150%。 这比去年同期每股亏损$(0.19)增加了105.26%。 公司报告的季度销售额为$59.87百万,低于分析师一致预期的$59.94百万,差距为0.13%。 与去年同期$45.09百万的销售额相比,这增加了32.76%。

以上内容来自Benzinga Earnings专栏,原文如下:

Aurinia Pharmaceuticals (NASDAQ:AUPH) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.02) by 150 percent. This is a 105.26 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $59.87 million which missed the analyst consensus estimate of $59.94 million by 0.13 percent. This is a 32.76 percent increase over sales of $45.09 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10